BMO Capital analyst Evan Seigerman upgraded Replimune (REPL) to Market Perform from Underperform with a price target of $11, up from $2. The firm ...

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

BLA submission of RP1 in combination with Bristol Myers Squibb's (BMY) Opdivo (nivolumab) for advanced melanoma. Shares are up ~108% in pre-market trading Monday. RP1 would be used in patients who ...

Microsoft’s cross-platform .NET takes interesting dependencies, including a fork of Google’s Skia, now to be co-maintained with Uno Platform.

Dozens of cemeteries across Ohio will soon receive financial assistance to help preserve their history and make them safer for visitors. The Ohio Department of Commerce’s Division of Real Estate and ...

Rollercoaster Tycoon wasn’t the most fashionable computer game out there in 1999. But if you took a look beneath the pixels—the rickety rides, the crowds of hungry, thirsty, barfing people (and the ...

Dozens of cemeteries across Ohio will soon receive financial assistance to help preserve their history and make them safer for visitors. The Ohio Department of Commerce’s Division of Real Estate and ...

The NBA is shaking up the way it offers its content later this week, taking a 24/7 programming approach for its mobile app and television channel. The league announced Monday, Oct. 13 that NBA TV and ...

Features case studies on successfulautomation implementations forcommercial mining operationsat scalein Australia SHENZHEN, ...

SPRINGFIELD, Mo. (KY3) - KY3 programming has returned to YouTube TV, Hulu, Fubo, and Peacock. KY3 worked with NBC throughout the week to fix a technical issue related to the outage. KY3 apologizes for ...

DENVER – Scams targeting older Americans are surging, and federal officials are warning that the tactics are becoming harder to detect. The Federal Trade Commission says scammers are posing as IRS ...

Qure (QURE) shares drop after FDA questions AMT-130 data for Huntington’s disease, delaying BLA submission. Read more here.